Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in lewis rats

Cellular and Molecular Life Sciences

Volumn 57, Issue 10, 2000, Pages 1457-1470

  Feige, U ^a   Hu, Y L ^a   Gasser, J ^a   Campagnuolo, G ^a   Munyakazi, L ^a   Bolon, B ^a  

^a AMGEN INC   (United States)

Author keywords

Adjuvant arthritis; Cytokine; IL 1ra; Interleukin 1; Rat; Rheumatoid arthritis; Soluble receptor; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MACROGOL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADJUVANT ARTHRITIS; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; INFLAMMATION; MALE; NONHUMAN; OSMOTIC MINIPUMP; RAT; RHEUMATOID ARTHRITIS;

ANIMALIA;

EID: 0033769803     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000629     Document Type: Article

References (66)

1. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
2. Role of cytokines in rheumatoid arthritis
3. Rheumatoid arthritis
4. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin
5. Cytokine production in culture by cells isolated from the synovial membrane
6. Cytokine expression in rheumatoid arthritis
7. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
8. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease
9. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
10. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
11. Interleukin-1 receptor antagonist
12. Anti-TNF-(agents in the treatment of inflammation
13. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
14. The role of tumor necrosis factor antagonism in clinical practice
15. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
16. Neutralization of interleukin-1(activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response
17. Influence of recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice
18. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice
19. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment
20. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis
21. Role of interleukin-1, tumor necrosis factor alpha and interleukin-6 in cartilage proteoglycan metabolism and destruction
22. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNF-alpha, anti-IL-1 alpha/ beta and IL-1Ra
23. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis
24. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: Comparison of efficacy in animal models with human clinical data
25. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: Correlation of plasma levels with efficacy
26. Future trends in the treatment of rheumatoid arthritis: Cytokine targets
27. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategy
28. Arthritogenic actions of recombinant IL-1 and tumor necrosis factor (in the rabbit: Evidence for synergistic interactions between cytokines in vivo
29. Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes
30. Synergistic, additive, and antagonistic effects of interleukin-1 beta, tumor necrosis factor alpha, and gamma-interferon on prostaglandin E, hyaluronic acid, and collagenase production by cultured synovial fibroblasts
31. Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on PGE2 production by articular chondrocytes does not involve PLA2 stimulation
32. Interleukin 1 and tumor necrosis factor-alpha synergistically increase the production of interleukin 6 in human synovial fibroblast
33. Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on interleukin-8 gene expression in synovial fibroblasts: Evidence that interleukin-8 is the major neutrophil-activating chemokine released in response to monokine activation
34. Regulation of expression of human IL-1 alpha and IL-1 beta genes
35. Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits
36. Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: Comparison with the effects of tumour necrosis factor
37. Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: Improved survival and organ function
38. Combined treatment of acute EAE in Lewis rats with TNF-binding protein and interleukin-1 receptor antagonist
39. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in early postovariectomy period
40. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice
41. Distal metacarpal bone mineral density by dual energy X-ray absorptiometry (DEXA) scan: Methodological investigation and application in rheumatoid arthritis
42. Bone mineral density in ambulant, non-steroid treated female patients with rheumatoid arthritis
43. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function
44. Short-term low dose methotrexate ameliorates abnormal bone metabolism and bone loss in adjuvant induced arthritis
45. Changes in bone mineral density in rat adjuvant arthritis
46. Studies of arthritis and other lesions induced in rats by the injection of mycobacterial adjuvant
47. Treatment of adjuvant arthritis in rats: Vaccination potential of a synthetic nonapeptide from the 65 kDa heat shock protein of mycobacteria
48. Dual-energy X-ray absorptiometry of the rat: Accuracy, precision, and measurement of bone loss
49. The use of dual-energy X-ray absorptiometry in animals
50. Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metallo-proteinases and TNFα processing
51. Bone mass assessment in rats by dual energy X-ray absorptiometry
52. Criteria for analyzing interactions between biological active agents
53. What is synergy?
54. A statistical approach to the construction and analysis of isobolograms
55. Synergy, antagonism, and potentiation in chemotherapy: An overview
56. Combining anti-IL-1 and anti-TNF treatments provides better efficacy in a rat adjuvant arthritis model than does either agent alone
57. Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist (IL-1ra) and PEGy-lated recombinant human soluble tumor necrosis factor receptor type I (PEG sTNF-RI) in animal models of rheumatoid arthritis
58. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist
59. The role of tumor necrosis factor in health and disease
60. Major role for interleukin-1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice
61. Joint inflammation and cartilage destruction may occur uncoupled. Springer Semin
62. Role of tumour necrosis factor α in experimental arthritis: Separate activity of interleukin 1β in chronicity and cartilage destruction
63. Comparison of etanercept vs. methotrexate in early rheumatoid arthritis using gadolinium enhanced magnetic resonance imaging
64. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis
65. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand